Biogen (BIIB)
(Delayed Data from NSDQ)
$224.00 USD
-1.58 (-0.70%)
Updated Jun 21, 2024 04:00 PM ET
After-Market: $224.09 +0.09 (0.04%) 7:58 PM ET
C Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
BIIB 224.00 -1.58(-0.70%)
Will BIIB be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIIB
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
Other News for BIIB
GLP-1 drugs linked to reduced dementia risk: study
Eli Lilly: The Party Is Probably Nearing The End
Eli Lilly And Alzheimer's Disease: The Paucity Of Progress
The 3 Best Healthcare Stocks to Buy in June 2024
ALS therapy market seen increasing to nearly $1.3B by 2029